{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:59:44Z","timestamp":1790510384540,"version":"4.1.0"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1681\/asn.2017030361","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T21:03:26Z","timestamp":1674248606000},"page":"906-918","source":"Crossref","is-referenced-by-count":65,"title":["Indoxyl Sulfate Upregulates Liver P-Glycoprotein Expression and Activity through Aryl Hydrocarbon Receptor Signaling"],"prefix":"10.1681","volume":"29","author":[{"given":"Tacy","family":"Santana Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Poitevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Jourde-Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Legris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Mouly-Bandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Dignat-George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinde","family":"Masereeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Cerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"key":"B1-20230120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2215\/CJN.00290109","article-title":"Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.","volume":"4","author":"Chiu","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3-20230120","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/MNH.0b013e328349c261","article-title":"Polypharmacy and medication-related complications in the chronic kidney disease patient.","volume":"20","author":"Mason","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B4-20230120","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","article-title":"Pharmacokinetics and dosage adjustment in patients with renal dysfunction.","volume":"65","author":"Verbeeck","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"B5-20230120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/sdi.12374","article-title":"A synopsis of clinical pharmacokinetic alterations in advanced CKD.","volume":"28","author":"Nolin","year":"2015","journal-title":"Semin Dial"},{"key":"B6-20230120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ki.2013.399","article-title":"Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.","volume":"85","author":"Yeung","year":"2014","journal-title":"Kidney Int"},{"key":"B7-20230120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do?","volume":"14","author":"Nigam","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B8-20230120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0074-7696(06)60002-8","article-title":"Molecular mechanism of phase I and phase II drug-metabolizing enzymes: Implications for detoxification.","volume":"260","author":"Iyanagi","year":"2007","journal-title":"Int Rev Cytol"},{"key":"B9-20230120","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1211\/0022357001777676","article-title":"Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction.","volume":"52","author":"Okabe","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"B10-20230120","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/01.ASN.0000017575.50319.77","article-title":"Downregulation of intestinal cytochrome p450 in chronic renal failure.","volume":"13","author":"Leblond","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B11-20230120","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1681\/ASN.2009010082","article-title":"ESRD impairs nonrenal clearance of fexofenadine but not midazolam.","volume":"20","author":"Nolin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B12-20230120","doi-asserted-by":"crossref","first-page":"e18438","DOI":"10.1371\/journal.pone.0018438","article-title":"Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.","volume":"6","author":"Mutsaers","year":"2011","journal-title":"PLoS One"},{"key":"B13-20230120","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.tiv.2015.07.020","article-title":"Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology.","volume":"29","author":"Mutsaers","year":"2015","journal-title":"Toxicol In Vitro"},{"key":"B14-20230120","doi-asserted-by":"crossref","first-page":"R1488","DOI":"10.1152\/ajpregu.00371.2014","article-title":"Effects of chronic kidney disease on liver transport: Quantitative intravital microscopy of fluorescein transport in the rat liver.","volume":"307","author":"Ryan","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B15-20230120","first-page":"475","article-title":"Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.","volume":"17","author":"Sato","year":"2014","journal-title":"J Pharm Sci"},{"key":"B16-20230120","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1046\/j.1523-1755.2003.00924.x","article-title":"Review on uremic toxins: Classification, concentration, and interindividual variability.","volume":"63","author":"Vanholder","year":"2003","journal-title":"Kidney Int"},{"key":"B17-20230120","doi-asserted-by":"crossref","first-page":"e0132589","DOI":"10.1371\/journal.pone.0132589","article-title":"Meta-analysis of the associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure.","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"key":"B18-20230120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/nep.12580","article-title":"Indoxyl sulphate and kidney disease: Causes, consequences and interventions.","volume":"21","author":"Ellis","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"B19-20230120","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2215\/CJN.03980609","article-title":"Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.","volume":"4","author":"Barreto","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20230120","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3390\/toxins6030934","article-title":"The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: A new concept to understand cardiovascular complications of chronic kidney disease.","volume":"6","author":"Sall\u00e9e","year":"2014","journal-title":"Toxins (Basel)"},{"key":"B21-20230120","first-page":"60","article-title":"Chronic kidney disease and fibrosis: The role of uremic retention solutes.","volume":"2","author":"Mutsaers","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"B22-20230120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/bi901786x","article-title":"The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.","volume":"49","author":"Schroeder","year":"2010","journal-title":"Biochemistry"},{"key":"B23-20230120","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1515\/BC.2009.138","article-title":"The mammalian aryl hydrocarbon (Ah) receptor: From mediator of dioxin toxicity toward physiological functions in skin and liver.","volume":"390","author":"Bock","year":"2009","journal-title":"Biol Chem"},{"key":"B24-20230120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ki.2013.133","article-title":"Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway.","volume":"84","author":"Gondouin","year":"2013","journal-title":"Kidney Int"},{"key":"B26-20230120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.mam.2012.10.010","article-title":"The SLC22 family with transporters of organic cations, anions and zwitterions.","volume":"34","author":"Koepsell","year":"2013","journal-title":"Mol Aspects Med"},{"key":"B27-20230120","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13238-015-0148-2","article-title":"The physiological role of drug transporters.","volume":"6","author":"Liang","year":"2015","journal-title":"Protein Cell"},{"key":"B28-20230120","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jchromb.2011.06.014","article-title":"Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay.","volume":"879","author":"Calaf","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"B29-20230120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/bdd.1834","article-title":"Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate.","volume":"34","author":"Viaene","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"B30-20230120","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2011121213","article-title":"Npt2b deletion attenuates hyperphosphatemia associated with CKD.","volume":"23","author":"Schiavi","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B31-20230120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1681\/ASN.2004060495","article-title":"Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice.","volume":"16","author":"Massy","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B32-20230120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/bph.12932","article-title":"Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease.","volume":"172","author":"Feere","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B33-20230120","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter.","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B34-20230120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/138920008783331086","article-title":"Cell lines: A tool for in vitro drug metabolism studies.","volume":"9","author":"Donato","year":"2008","journal-title":"Curr Drug Metab"},{"key":"B35-20230120","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.tiv.2015.03.019","article-title":"Polarized location of SLC and ABC drug transporters in monolayer-cultured human hepatocytes.","volume":"29","author":"Le Vee","year":"2015","journal-title":"Toxicol In Vitro"},{"key":"B36-20230120","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1091\/mbc.e06-03-0230","article-title":"Efficient trafficking of MDR1\/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RIIalpha anchoring and glucosylceramide.","volume":"17","author":"Wojtal","year":"2006","journal-title":"Mol Biol Cell"},{"key":"B37-20230120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1744-9987.2012.01100.x","article-title":"Influence of serum in hemodialysis patients on the expression of intestinal and hepatic transporters for the excretion of pravastatin.","volume":"16","author":"Tsujimoto","year":"2012","journal-title":"Ther Apher Dial"},{"key":"B38-20230120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000365014","article-title":"Chronic kidney disease results in deficiency of ABCC6, the novel inhibitor of vascular calcification.","volume":"40","author":"Lau","year":"2014","journal-title":"Am J Nephrol"},{"key":"B39-20230120","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.106.010033","article-title":"Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes.","volume":"34","author":"Jigorel","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"B40-20230120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr218","article-title":"Exactly the same but different: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor.","volume":"124","author":"Denison","year":"2011","journal-title":"Toxicol Sci"},{"key":"B41-20230120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.pa.35.040195.001515","article-title":"The aryl hydrocarbon receptor complex.","volume":"35","author":"Hankinson","year":"1995","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B42-20230120","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1681\/ASN.2013121283","article-title":"The cardiovascular effect of the uremic solute indole-3 acetic acid.","volume":"26","author":"Dou","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B43-20230120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.acr.2014.10.002","article-title":"Regulation of ABC transporters blood-brain barrier: The good, the bad, and the ugly.","volume":"125","author":"Miller","year":"2015","journal-title":"Adv Cancer Res"},{"key":"B44-20230120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.pharmtox.43.100901.135828","article-title":"Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals.","volume":"43","author":"Denison","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B45-20230120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.smim.2011.01.008","article-title":"External influences on the immune system via activation of the aryl hydrocarbon receptor.","volume":"23","author":"Stockinger","year":"2011","journal-title":"Semin Immunol"},{"key":"B46-20230120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3846","article-title":"Aryl hydrocarbon receptor ligands in cancer: Friend and foe.","volume":"14","author":"Murray","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B47-20230120","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/mol.111.075952","article-title":"A novel nonconsensus xenobiotic response element capable of mediating aryl hydrocarbon receptor-dependent gene expression.","volume":"81","author":"Huang","year":"2012","journal-title":"Mol Pharmacol"},{"key":"B48-20230120","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/jcbfm.2011.44","article-title":"Activating PKC-\u03b21 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS.","volume":"31","author":"Wang","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"B49-20230120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ymgme.2010.08.019","article-title":"Functional analysis of genetic variations in the 5\u2032-flanking region of the human MDR1 gene.","volume":"102","author":"Saeki","year":"2011","journal-title":"Mol Genet Metab"},{"key":"B50-20230120","doi-asserted-by":"crossref","first-page":"26715","DOI":"10.1038\/srep26715","article-title":"Bioengineered kidney tubules efficiently excrete uremic toxins.","volume":"6","author":"Jansen","year":"2016","journal-title":"Sci Rep"},{"key":"B51-20230120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.11.013","article-title":"Modulation of P-glycoprotein efflux pump: Induction and activation as a therapeutic strategy.","volume":"149","author":"Silva","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B52-20230120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/dmd.107.018192","article-title":"Effects of chronic renal failure on liver drug transporters.","volume":"36","author":"Naud","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 5","key":"B53-20230120","first-page":"46","article-title":"Excretion of cyclosporine and its metabolites in human bile.","volume":"18","author":"Burckart","year":"1986","journal-title":"Transplant Proc"},{"key":"B54-20230120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yrtph.2013.10.006","article-title":"Effect of uremic serum and uremic toxins on drug metabolism in human microsomes.","volume":"68","author":"Volpe","year":"2014","journal-title":"Regul Toxicol Pharmacol"},{"key":"B55-20230120","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00228-014-1709-7","article-title":"Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.","volume":"70","author":"Barnes","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"B56-20230120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bcpt.12371","article-title":"The effect of ABCB1 C3435T polymorphism on cyclosporine dose requirements in kidney transplant recipients: A meta-analysis.","volume":"117","author":"Lee","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B57-20230120","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/tri.12018","article-title":"Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study.","volume":"26","author":"Llaud\u00f3","year":"2013","journal-title":"Transpl Int"},{"key":"B58-20230120","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1172\/JCI118214","article-title":"Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.","volume":"96","author":"Schinkel","year":"1995","journal-title":"J Clin Invest"},{"key":"B59-20230120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4103\/ijn.IJN_71_17","article-title":"Role of gut-derived uremic toxins on oxidative stress and inflammation in patients with chronic kidney disease.","volume":"27","author":"Gouroju","year":"2017","journal-title":"Indian J Nephrol"},{"key":"B60-20230120","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/j.1538-7836.2009.03540.x","article-title":"Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients.","volume":"7","author":"Jourde-Chiche","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B61-20230120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/dmd.113.054171","article-title":"Association of plasma concentration of 4\u03b2-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients.","volume":"42","author":"Suzuki","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"B62-20230120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12882-016-0387-3","article-title":"Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian chronic kidney disease pilot study.","volume":"17","author":"Karu","year":"2016","journal-title":"BMC Nephrol"},{"key":"B63-20230120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/j.ackd.2010.05.009","article-title":"Nonrenal drug clearance in CKD: Searching for the path less traveled.","volume":"17","author":"Momper","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"B64-20230120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8020012","article-title":"Evaluation of P-glycoprotein inhibitory potential using a rhodamine 123 accumulation assay.","volume":"8","author":"Jouan","year":"2016","journal-title":"Pharmaceutics"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201803000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:24:52Z","timestamp":1786130692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201803000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,8]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2017030361","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,8]]}}}